

Application
Type/Number

Submission
Type/Number

Submitter Name

Product Name

NDA-22187

SUPPL-3

TIBOTEC INC

TMC 125 ETRAVIRINE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS

02/23/2010

HUMATIN - paromomycin sulfate capsule
Monarch Pharmaceuticals, Inc.

DESCRIPTION

Humatin is a broad spectrum antibiotic produced by *Streptomyces rimosus* var. *paromomycinus*. It is a white, amorphous, stable, water-soluble product supplied as capsules containing the equivalent of 250 mg paromomycin. The capsule contains D&C yellow No. 10; FD&C blue No. 1; FD&C red No. 3; FD&C yellow No. 6; gelatin, NF; and titanium dioxide, USP.

ACTION

The *in vitro* and *in vivo* antibacterial action of paromomycin closely parallels that of neomycin. It is poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.

INDICATIONS

Humatin is indicated for intestinal amebiasis—acute and chronic (NOTE —It is not effective in extraintestinal amebiasis); management of hepatic coma—as adjunctive therapy.

CONTRAINDICATIONS

Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.

PRECAUTIONS

The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken.

The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.

Pediatric Use: See **Dosage and Administration** section.

ADVERSE REACTIONS

Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily.

DOSAGE AND ADMINISTRATION

Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.

Management of hepatic coma: Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.

HOW SUPPLIED

Humatin Capsules, each containing paromomycin sulfate equivalent to 250 mg paromomycin, are supplied as follows

NDC 61570-529-10: Bottles of 100

Store at controlled room temperature 15°–30°C (59°–86°F).

Protect from moisture.

Rx only.

Prescribing Information as of November 2001.

Distributed by: Monarch Pharmaceuticals, Inc., Bristol, TN 37620

Manufactured by: Caraco Pharmaceutical Laboratories, Ltd., Detroit, MI 48202

平成22(2009)年3月 発行

厚生労働科学研究費補助金

創薬基盤推進研究事業：政策創薬総合研究事業

厚生労働省 エイズ治療薬研究班

国内未承認エイズ治療薬等を用いたHIV感染症治療薬

及びHIV感染症至適治療法の開発に係る応用研究

平成19年度～21年度 総合研究報告書

研究代表者 福武 勝幸

事務局

〒160-0023 東京都新宿区西新宿 6-7-1

東京医科大学病院 臨床検査医学講座

電話 03-3342-6111

